Dr Reddy’s Settles US Patent Litigation With Intercept On Ocaliva
Five Further Firms Have Filed For Generic Obeticholic Acid
Dr Reddy’s is the first of six generics firms to challenge Intercept’s Ocaliva patents to reach a settlement, and will be able to market its product in the US from 2035 onward.
